HJ Science Co., Ltd. (HKG:6132)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
33.02
-0.58 (-1.73%)
Jul 10, 2026, 10:30 AM HKT
Market Cap2.47B
Revenue (ttm)14.54M +407.8%
Net Income-150.32M
EPS-2.54
Shares Out 73.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,500
Open33.30
Previous Close33.60
Day's Range32.00 - 33.62
52-Week Range30.78 - 82.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About HJ Science

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the treatment of atopic dermatitis (AD) and acne vulgaris (AV); HJ178, an orally available agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection intended for the treatment of non-small-cell lung cancer (NSCLC). It is also developing HJ197 in clinical-stage for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6132
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements